Abstract 217P
Background
With conditional reprogramming (CR) technique to generate continuous primary cancer cell cultures from bladder cancer patients’ urine samples, we aimed to establish a novel in vitro model by a rapid and non-invasive method to predict clinical response to anti-tumor drugs including immunotherapy and provide drug guidance for patients.
Methods
Patients included were all diagnosed with bladder cancer, among which were 54 high grade and 14 low grade. Urine and tumor samples were collected before therapeutic treatment. The overall success rate was summarized. Whole-exome sequencing (WES) and short tandem repeat (STR) analysis were utilized to confirm the authentication of CR cultures (CRCs). Dose-response measurements were used to generate drug sensitivity scores. Expression of PD-L1 on the cell surface of urine CRCs after IFN-γ treatment is evaluated with flow cytometry.
Results
The overall success rate of establishing urine CRCs was 87.2% (68/78), with 93.1% (54/58) of high grade bladder cancer, 70.0% (14/20) of low grade bladder cancer. Importantly, the in vitro drug sensitivity results of the urine-derived cells exhibited strong consistency (78%) with the clinical responses to treatment, indicating their potential for guiding patient-specific therapeutic strategies. Furthermore, we revealed that IFN-γ-stimulated PD-L1 expression on urine CRCs could predict the prognosis of bladder cancer patients and exhibited predictive value for ICI response in bladder cancer patients with a significant consistency of 88%, highlighting their clinical relevance.
Conclusions
Our study demonstrates the successful establishment of a reliable and patient-specific bladder cancer cell model derived from urine samples which serve to guide anti-tumor drugs and immunotherapeutic interventions. The findings underscore the clinical utility and translational potential of urine-derived cells for personalized bladder cancer management.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Zhongshan Hospital Fudan University.
Funding
National Natural Science Foundation of China.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
571P - Dacomitinib in treatment-naïve EGFR-mutant NSCLC patients with multiple brain metastases: Initial efficacy and safety data from a phase II study
Presenter: Yongfeng Yu
Session: Poster Display
Resources:
Abstract
572P - Multivariable five-year survival prediction model for prognosing patients with EGFR-mutated NSCLC treated with EGFR-TKIs
Presenter: Qi-An Wang
Session: Poster Display
Resources:
Abstract
573P - LUMINATE-103: Real-world treatment patterns and outcomes of patients (pts) with epidermal growth factor receptor mutant (EGFR MU), non-squamous (NSQ) locally advanced/metastatic non-small cell lung cancer (a/mNSCLC): Pooled analysis of large US electronic health record (EHR) datasets
Presenter: Byoung Chul Cho
Session: Poster Display
Resources:
Abstract
574P - Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC harboring uncommon EGFR mutations
Presenter: Lin Wu
Session: Poster Display
Resources:
Abstract
575P - Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC and brain metastasis: A multicenter cohort study
Presenter: Puyuan Xing
Session: Poster Display
Resources:
Abstract
576P - Clonality of both EGFR and co-occurring TP53 mutations affect the treatment efficacy of the third-generation EGFR-TKIs in advanced-stage EGFR-mutant non-small cell lung cancer
Presenter: Wen Feng Fang
Session: Poster Display
Resources:
Abstract
577P - A study of the efficacy and safety of amivantamab in EGFR exon 20 insertion (E20I) mutations in NSCLC
Presenter: Daeho Choi
Session: Poster Display
Resources:
Abstract
578P - Tyrosine kinase inhibitor treatment of elderly patients with epidermal growth factor receptor mutated advanced non-small cell lung cancer: A multi-institute retrospective study
Presenter: Ling-Jen Hung
Session: Poster Display
Resources:
Abstract
579P - Real-world study of dacomitinib as first-line treatment for patients with EGFR-mutant non-small cell lung cancer
Presenter: Ji Eun Shin
Session: Poster Display
Resources:
Abstract
580P - Efficacy and safety of dacomitinib as first-line treatment for advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor <italic>(EGFR)</italic> 21L858R mutation: A multicenter, ambispective, consecutive case-series study
Presenter: Shouzheng Wang
Session: Poster Display
Resources:
Abstract